JP7868817B2 - 糖尿病に対するsHB-EGF強化治療 - Google Patents

糖尿病に対するsHB-EGF強化治療

Info

Publication number
JP7868817B2
JP7868817B2 JP2025558591A JP2025558591A JP7868817B2 JP 7868817 B2 JP7868817 B2 JP 7868817B2 JP 2025558591 A JP2025558591 A JP 2025558591A JP 2025558591 A JP2025558591 A JP 2025558591A JP 7868817 B2 JP7868817 B2 JP 7868817B2
Authority
JP
Japan
Prior art keywords
egf
ecd
nucleic acid
aav
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025558591A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2025211357A1 (cg-RX-API-DMAC7.html
JPWO2025211357A5 (cg-RX-API-DMAC7.html
Inventor
健一郎 小戝
恵理子 松田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SURV BIOPHARMA INC.
Kagoshima University
Original Assignee
SURV BIOPHARMA INC.
Kagoshima University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SURV BIOPHARMA INC., Kagoshima University filed Critical SURV BIOPHARMA INC.
Publication of JPWO2025211357A1 publication Critical patent/JPWO2025211357A1/ja
Publication of JPWO2025211357A5 publication Critical patent/JPWO2025211357A5/ja
Application granted granted Critical
Publication of JP7868817B2 publication Critical patent/JP7868817B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2025558591A 2024-04-02 2025-04-01 糖尿病に対するsHB-EGF強化治療 Active JP7868817B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2024059835 2024-04-02
JP2024059835 2024-04-02
PCT/JP2025/013342 WO2025211357A1 (ja) 2024-04-02 2025-04-01 糖尿病に対するsHB-EGF強化治療

Publications (3)

Publication Number Publication Date
JPWO2025211357A1 JPWO2025211357A1 (cg-RX-API-DMAC7.html) 2025-10-09
JPWO2025211357A5 JPWO2025211357A5 (cg-RX-API-DMAC7.html) 2026-03-11
JP7868817B2 true JP7868817B2 (ja) 2026-06-02

Family

ID=97267051

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025558591A Active JP7868817B2 (ja) 2024-04-02 2025-04-01 糖尿病に対するsHB-EGF強化治療

Country Status (3)

Country Link
JP (1) JP7868817B2 (cg-RX-API-DMAC7.html)
TW (1) TW202602484A (cg-RX-API-DMAC7.html)
WO (1) WO2025211357A1 (cg-RX-API-DMAC7.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020158690A1 (ja) 2019-01-28 2020-08-06 東レ株式会社 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
WO2022186282A1 (ja) 2021-03-03 2022-09-09 国立大学法人 鹿児島大学 糖尿病に対するhb-egf遺伝子治療

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4839476B2 (ja) * 2005-09-28 2011-12-21 国立大学法人 鹿児島大学 ヘパリン結合性上皮増殖因子様増殖因子の新規医薬用途
JP2007223939A (ja) * 2006-02-22 2007-09-06 Kobe Univ エネルギー代謝促進因子としてのhb−egfの使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020158690A1 (ja) 2019-01-28 2020-08-06 東レ株式会社 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
WO2022186282A1 (ja) 2021-03-03 2022-09-09 国立大学法人 鹿児島大学 糖尿病に対するhb-egf遺伝子治療

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Hepatology Research,2011年,41,pp. 594-596
Molecular and Cellular Biology,2019年07月01日,Vol. 39, No. 14,pp. 1-20,DOI: 10.1128/MCB.00140-19
Protein and Peptide Letters,2004年10月01日,Vol. 11, No. 5,pp.443-450,DOI: 10.2174/0929866043406562
日本血栓止血学会誌,2006年,Vol. 27, No. 1, pp. 77-84

Also Published As

Publication number Publication date
WO2025211357A1 (ja) 2025-10-09
JPWO2025211357A1 (cg-RX-API-DMAC7.html) 2025-10-09
TW202602484A (zh) 2026-01-16

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251006

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251006

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20251021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251023

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20251105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260414

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260512

R150 Certificate of patent or registration of utility model

Ref document number: 7868817

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150